Chemotherapy Combined With Apatinib and PD-1 Antibody
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
The effective rate of second-line and later-line single-agent therapy for advanced gastric
cancer is limited. This research plan aims to explore whether the combination of drugs can
further improve the benefits of second-line and above therapies. Previous studies have shown
that there is a significant synergistic effect between chemotherapy and PD-1 monoclonal
antibody, or anti-angiogenic TKI drugs and PD-1 monoclonal antibody. This project is planned
to be based on the classic chemotherapy drugs irinotecan or paclitaxel, combined with
mesylate Apatinib and PD-1 monoclonal antibody, explore the effectiveness and safety of this
three-drug combination regimen for the second-line and above treatment of advanced gastric
cancer, in order to provide a better late-line treatment plan for patients with advanced
gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital